Association of an oral formulation of angiotensin-(1-7) with atenolol improves lipid metabolism in hypertensive rats

Peptides. 2013 May:43:155-9. doi: 10.1016/j.peptides.2013.03.009. Epub 2013 Mar 18.

Abstract

The β-adrenergic blockers and antagonists of the renin-angiotensin system (RAS) are among the drugs that present better results in the control of cardio-metabolic diseases. The aim of the present study was to evaluate the effect of the association of the β-blocker, atenolol, and an oral formulation of Ang-(1-7) on lipid metabolism in spontaneously hypertensive rats (SHR). The main results showed that SHR treated with oral formulation of Ang-(1-7) in combination to atenolol have an improvement of lipid metabolism with a reduction of total plasma cholesterol, improvement of oral fat load tolerance and an increase in the lipolytic response stimulated by the β-adrenergic agonist, isoproterenol, without modification of resting glucose or insulin sensitivity in adipocytes. In conclusion, we showed that administration of an Ang-(1-7) oral formulation in association with a β-blocker induces beneficial effects on dyslipidemia treatment associated with hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adrenergic beta-Antagonists / administration & dosage
  • Adrenergic beta-Antagonists / pharmacology*
  • Angiotensin I / administration & dosage*
  • Angiotensin I / pharmacology*
  • Animals
  • Atenolol / administration & dosage*
  • Atenolol / pharmacology*
  • Hypertension / metabolism*
  • Lipid Metabolism / drug effects*
  • Male
  • Peptide Fragments / administration & dosage*
  • Peptide Fragments / pharmacology*
  • Rats
  • Rats, Inbred SHR

Substances

  • Adrenergic beta-Antagonists
  • Peptide Fragments
  • Atenolol
  • Angiotensin I
  • angiotensin I (1-7)